Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.31 |
| ▸ | KIT | P10721 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21626828 | 0.79 | DYRK1A (0.38) | FGFR1FGFR2PDGFRBKITKDR | |
| SCHEMBL21626898 | 0.77 | CHEK1 (0.33) | CHEK1FGFR1FGFR2PDGFRBKIT | |
| SCHEMBL27893617 | 0.67 | BRD4 (0.34) | FGFR1FGFR2KITKDRAURKB | |
| SCHEMBL7513614 | 0.67 | CHEK1 (0.45) | CHEK1FGFR1PDGFRBKDRAURKB | |
| SCHEMBL30280407 | 0.67 | CHEK1 (0.45) | CHEK1FGFR1PDGFRBKDRAURKB | |
| SCHEMBL1565081 | 0.67 | CHEK1 (0.45) | CHEK1FGFR1PDGFRBKDRAURKB | |
| SCHEMBL2041300 | 0.66 | NR4A2 (0.47) | CHEK1FGFR1PDGFRBKDRAURKB | |
| SCHEMBL10260194 | 0.66 | DYRK1A (0.40) | FGFR1KITKDRAURKB | |
| SCHEMBL22516586 | 0.66 | BRD4 (0.55) | FGFR2KITKDR | |
| SCHEMBL21626790 | 0.65 | DYRK1B (0.36) | CHEK1FGFR1FGFR2PDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253571-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | WUXI LIFE FOUNTAIN BIOTECH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| EP-3825314-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | Medshine Discovery Inc. (CN) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020015744-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | 南京明德新药研发有限公司 | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253571-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | MET, FGFR1, FGFR2 | CHEK1 649/4885FGFR1 2/4885FGFR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.